Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 11,390,000 shares, a decrease of 6.9% from the March 31st total of 12,240,000 shares. Based on an average trading volume of 2,060,000 shares, the days-to-cover ratio is currently 5.5 days. Approximately 8.9% of the shares of the stock are short sold.
Institutional Trading of Aurinia Pharmaceuticals
Several hedge funds have recently bought and sold shares of AUPH. China Universal Asset Management Co. Ltd. raised its holdings in Aurinia Pharmaceuticals by 95.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company's stock worth $29,000 after buying an additional 1,798 shares during the period. Vermillion & White Wealth Management Group LLC bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $30,000. Tidemark LLC bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $39,000. DekaBank Deutsche Girozentrale bought a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter worth approximately $65,000. Finally, Eagle Asset Management Inc. bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $92,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have commented on AUPH. Royal Bank of Canada decreased their price objective on shares of Aurinia Pharmaceuticals from $13.00 to $8.00 and set an "outperform" rating on the stock in a report on Friday, February 16th. HC Wainwright reissued a "buy" rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, March 1st. Jefferies Financial Group cut their target price on shares of Aurinia Pharmaceuticals from $9.50 to $9.00 and set a "hold" rating on the stock in a research report on Friday, February 16th. Finally, Cantor Fitzgerald cut their target price on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $10.00.
Read Our Latest Stock Analysis on AUPH
Aurinia Pharmaceuticals Trading Up 2.0 %
Shares of NASDAQ:AUPH traded up $0.10 during mid-day trading on Monday, reaching $5.01. The stock had a trading volume of 939,961 shares, compared to its average volume of 2,125,059. The firm has a market cap of $724.55 million, a PE ratio of -9.22 and a beta of 1.36. The firm has a 50 day simple moving average of $5.27 and a two-hundred day simple moving average of $7.19. The company has a current ratio of 5.50, a quick ratio of 4.99 and a debt-to-equity ratio of 0.20. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $12.43.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03). The firm had revenue of $45.10 million during the quarter, compared to analyst estimates of $45.00 million. Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative return on equity of 20.10%. The business's revenue was up 58.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.18) earnings per share. On average, research analysts predict that Aurinia Pharmaceuticals will post -0.06 EPS for the current fiscal year.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Articles
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
